Crescent Enterprises, the UAE-headquartered diversified business, and MIT Solve, an initiative of the Massachusetts Institute of Technology that advances technology-led solutions to global challenges, have announced the renewal of the $100,000 Crescent Enterprises AI for Social Innovation Prize
Crescent Enterprises
Crescent Enterprises, the leading multinational diversified business headquartered in the UAE, has received the Impact Seal, Gold Tier from Majra, the UAE’s national corporate social responsibility (CSR) fund, as part of the 2025 to 2027 Impact Seal cycle, in recognition of its sustained commitment to responsible business and measurable impact. The recognition was
XCath, a medical device company that is pioneering neuro-endovascular surgical robotics, part owned by Crescent Enterprises, announced today that it has secured $30 million in Series C funding, bringing the total raised since the company’s inception to $92 million. The latest funds will support XCath’s ongoing efforts to bring the world’s first commercially-practical
XCath, a medical device company dedicated to pioneering neuro-endovascular surgical robotics, and Crescent Enterprises, the founding and largest shareholder of XCath, have announced the successful first-in-human use of XCath’s EVR robotic system to treat three patients with complex brain aneurysms. The landmark procedures were performed at The Panama Clinic in Panama City,
CE-Ventures, the corporate venture capital platform of Crescent Enterprises, today announced its participation in the $7.7 million Series A funding round for India-based, research and development-led speciality chemicals company, Distil. Distil’s fundraise was led by CE-Ventures and Singapore-based Jungle Ventures with participation from strategic investors Rubamin, PI














